Innovation Should Help Fuel Growth in This China Biotech ETF

Growth opportunities are abounding in Chinese biotech. A confluence of regulatory reforms, industry talent, and the re-opening of the country’s capital markets have helped propel China’s biotech industry. Global management consulting firm McKinsey & Company delved deeper into...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.